Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab + ipilimumab versus nivolumab alone after complete resection of high-risk melanoma
2016-003729-41Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in melanoma comparing Nivolumab + ipilimumab with Nivolumab monotherapy (2 arms). Primary endpoint: Recurrence-free survival. Started Feb 2017; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2016-003729-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003729-41.